Jane Street’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jane Street’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,100	Closed	-$353K	–	4664
2016 Q2	$353K	Buy	+9,100	New	+$379K	﹤0.01%	3134

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Jane Street's EGRX Position: Q4 2024 in Review

Jane Street sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 25,837 shares — an estimated $96.4K sold.

Jane Street first reported a position in EGRX in Q1 2015 and held it in 18 quarters. The position peaked at $1.84M in Q1 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Jane Street reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Jane Street sold 25,837 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $96.4K.
Jane Street first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 18 quarters.
Jane Street's Eagle Pharmaceuticals, Inc. position peaked at $1.84M in Q1 2023.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Jane Street's 13F filing for Q4 2024, filed 14 Feb 2025.